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Introduction
Stress hyperglycaemia, which has been increasingly
studied and discussed in recent years (1–7), occurs as
a consequence of stress associated with the acute phase
of a disease (2–8). Stress activates the hypothalamus-
pituitary-adrenal axis and the autonomic nervous sys-
tem and initiates a cascade of metabolic processes
leading hyperglycaemia (9,10). Currently no strict and
widely accepted criteria for stress hyperglycaemia
exist; however, it is commonly defined as a transient
elevation of blood glucose to a level exceeding values
regarded as normal. In many, but not all, previous
studies the diagnosis of stress hyperglycaemia referred
exclusively to patients without prior diabetes who
presented with hyperglycaemia on hospital admission
for life-threatening conditions (3–7,11–13). These
patients are of particular interest to clinicians because
they are reported to have a worse prognosis than those
with diabetes despite higher blood glucose levels on
admission in the latter population (6,11,12,14,15).
There is a lack of studies comparing the occurrence of
stress hyperglycaemia in patients with and without
diabetes. Previous studies have not directly assessed
whether high admission glycaemia was merely a tem-
porary finding or a sign of pre-existing, but undiag-
nosed abnormalities. Moreover, despite proving very
high prevalence of abnormal glucose tolerance (AGT)
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oral glucose tolerance test on day 3 of hospitalisation and 3 months after dis-
charge. Results: Abnormal glucose tolerance at day 3 was observed in 92
(45.1%) patients without a previous diagnosis of diabetes mellitus and resolved
after 3 months in 46 (50.0%) patients (p < 0.0001). Stress hyperglycaemia,
defined as admission glycaemia ‡ 11.1 mmol ⁄ l, affected 34 (14.0%) study partici-
pants: 28 (54.9%) patients with diabetes vs. 3 (8.8%) subjects with newly
detected impaired glucose intolerance (p < 0.00001) and 1 (2.2%) person with
AGT at day 3 (p < 0.000001). Multivariable analysis identified elevated glycated
haemoglobin (HbA1c; p < 0.0000001), anterior MI (p < 0.05) and high admission
cortisol concentration (p < 0.001), but not catecholamines, as independent predic-
tors of stress hyperglycaemia. The receiver operating characteristic curve analysis
revealed the optimal cut-off values of 8.2% for HbA1c and 47.7 lg ⁄ dl for admis-
sion cortisol with very good and sufficient diagnostic accuracies respectively. Con-
clusions: Newly detected AGT in patients with a first MI is transient in 50% of
cases. Stress hyperglycaemia is a common finding in patients with a first MI with
ST-segment elevation and diabetes mellitus, but is rarely observed in individuals
with impaired glucose tolerance or transient AGT diagnosed during the acute
phase of MI. The risk factors of stress hyperglycaemia occurrence include elevated
HbA1c, anterior MI and high admission cortisol concentration.
What’s known
Stress hyperglycaemia is defined as a transient
elevation of blood glucose occurring in the acute
phase of a disease. Abnormal glucose tolerance
(AGT) observed in above 60% of patients with
acute myocardial infarction (MI) is a persistent
disturbance there. There is a lack of researches
assessing the prevalence of AGT in patients with a
first MI with ST-segment elevation and studies
comparing the occurrence of stress hyperglycaemia
in patients with and without AGT.
What’s new
Abnormal glucose tolerance in patients with a first
MI with ST-segment elevation is transient in 50%
of cases. Stress hyperglycaemia in this setting is a
common finding in patients with diabetes, but is
rarely observed in patients with newly detected
impaired glucose tolerance or transient AGT
diagnosed for the first time during MI. The risk
factors of stress hyperglycaemia occurrence include
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in patients with acute myocardial infarction (MI)
(16,17), there is a shortage of research assessing the
occurrence of newly diagnosed AGT and stress hyper-
glycaemia in the group of patients with first MI.
The aim of this study was to compare the inci-
dence of stress hyperglycaemia between patients with
and without diabetes in the selected group with a
first MI with ST-segment elevation, to investigate if
it is a manifestation of previously undiagnosed car-
bohydrate metabolism abnormalities and to assess
whether there is any relationship between admission
glycaemia and circulating levels of stress hormones
(adrenaline, noradrenaline and cortisol).
Material and methods
Study design and patient characteristics
The population of our prospective cohort study con-
sisted of 365 consecutive patients admitted to the
Department of Cardiology and Internal Medicine,
Collegium Medicum in Bydgoszcz, Poland, because
of a first episode of acute MI with ST-segment eleva-
tion. The diagnosis of MI was established accordingly
to the Joint European Society of Cardiology ⁄ Ameri-
can College of Cardiology Committee for the Redefi-
nition of Myocardial Infarction recommendations
published in 2007 (18). Exclusion criteria were as
follows: age > 80 years; therapy with vasopressors,
inotropes, steroids or immunosuppressants; severe
heart failure (class III or IV according to the New
York Heart Association Functional classification),
creatinine level > 176.8 lmol ⁄ l, neoplasm and symp-
tomatic infection. The study protocol was approved
by the Local Bioethics Committee at Collegium
Medicum of the Nicolaus Copernicus University in
Torun. All patients gave voluntary informed consent
for participation in the study.
Study conduction
Patients with initially established diagnosis of acute
coronary syndrome with ST-segment elevation were
transferred directly to the Invasive Cardiology Cathe-
terization Laboratory in the Department of Cardiol-
ogy and Internal Medicine. Blood samples were
taken on admission prior to coronary angiography to
measure: glucose, adrenaline, noradrenaline, total
cortisol, creatine kinase, creatine kinase MB isoen-
zyme, troponin I, glycated haemoglobin (HbA1c),
creatinine, total cholesterol, low-density-lipoprotein
cholesterol, high-density-lipoprotein cholesterol and
triglycerides. According to the Polish Diabetes Asso-
ciation recommendations (19) patients without dia-
betes with admission glycaemia > 10.0 mmol ⁄ l and
those with diabetes and admission glycaemia
> 7.8 mmol ⁄ l in the first 24 h of hospitalisation were
treated with insulin intravenously. Subsequently, in
patients with glycaemia above > 7.8 mmol ⁄ l subcuta-
neous insulin therapy in the form of multiple insulin
injections was applied from day 2 up to day 5.
In individuals without a previous diagnosis of dia-
betes, an oral glucose tolerance test (OGTT) with
75 g of glucose was performed on day 3 and again
3 months postdischarge. Glucose concentrations in
venous blood plasma 2 h after glucose intake were
classified as follows: normal glucose tolerance
< 7.77 mmol ⁄ l; impaired glucose tolerance from 7.77
up to 11.09 mmol ⁄ l; diabetes ‡ 11.1 mmol ⁄ l. Based
on the OGTT results at day 3 and month 3 the study
group was divided into four subgroups (Table 1): (i)
with AGT (defined as impaired glucose tolerance and
diabetes) recognised at day 3 and month 3, (ii) with
AGT present at day 3 and resolved at month 3, (iii)
with normal glucose tolerance (NGT) at day 3 and
month 3 and (iv) with NGT at day 3 and AGT at
month 3. Stress hyperglycaemia was recognised as
Table 1 Results of the oral glucose tolerance test (OGTT) performed on day 3 and 3 months postdischarge in 204
patients with the first ST-segment-elevation myocardial infarction and no previous diagnosis of type 2 diabetes
D3+ ⁄ M3+
n = 46 (22.5%)
D3+ ⁄ M3)
n = 46 (22.5%)
D3) ⁄ M3)
n = 94 (46.1%)
D3) ⁄ M3+
n = 18 (8.8%)
OGTT day 3: normal glucose tolerance – – 94 18
Impaired glucose tolerance 23 40 – –
Diabetes mellitus 23 6 – –
OGTT month 3: normal glucose tolerance – 46 94 –
Impaired glucose tolerance 32 – – 16
Diabetes mellitus 14 – – 2
D3+ ⁄ M3+, abnormal glucose tolerance diagnosed at day 3 and 3 months; D3+ ⁄ M3), abnormal glucose tolerance diagnosed at day 3
and ruled out at 3 months; D3) ⁄ M3), abnormal glucose tolerance ruled out at day 3 and 3 months; D3) ⁄ M3+, abnormal glucose
tolerance ruled out at day 3 and diagnosed at 3 months; OGTT, oral glucose tolerance test. Two patients from group D3+ ⁄ M3+ with
diabetes diagnosed in month 3 in OGTT performed on day 3 had impaired glucose tolerance.
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admission glycaemia ‡ 11.1 mmol ⁄ l based on the
definition of ‘hospital-related hyperglycaemia’ intro-
duced by The American Diabetes Association (20).
Laboratory analyses
Biochemical measurements were performed using the
following methods: blood glucose – hexokinase enzy-
matic glucose assay (Abbott, Wiesbaden, Germany);
HbA1c – immunoturbimetric Multigent
TM HbA1c
assay (Abbott, Indianapolis, USA); catecholamines –
fluorometry using a Shimadzu 1501 spectrophotome-
ter (Shimadzu, Kioto, Japan); cortisol – AxSYM
Cortisol assay (Abbott, Malvern, AR, USA); creatine
kinase – enzymatic method Creatine kinase assay
(Abbott, Chicago, IL, USA); creatine kinase MB iso-
enzyme – CK-MB liquid immunological test assay
(Sentinel Diagnostics, Milan, Italy); troponin I –
chemiluminescence immunoassay STAT Troponin-I
Architect System (Abbott, Middletown, OH, USA);
creatinine – spectrophotometric creatinine assay
(Abbott, Wiesbaden, Germany); total cholesterol,
high-density-lipoprotein cholesterol and triglycerides
– enzymatic cholesterol, ultrahigh-density-lipoprotein
and triglyceride assays (Abbott, Wiesbaden, Germany)
respectively. Low-density-lipoprotein cholesterol concen-
tration was calculated according to the Friedewald
formula.
Statistical analysis
Results are presented as mean values and standard
deviations for quantitative parameters and as percent-
ages of the population for categorical data. Use of the
Shapiro-Wilk test demonstrated that the investigated
quantitative variables were not normally distributed.
The significance of differences between groups was
evaluated using the ANOVA Kruskal–Wallis test and
Mann–Whitney U-test. The Wilcoxon rank test was
used to evaluate dependent samples. The McNemar’s
test and the v2 test (with Yates correction when
required) were used for paired and unpaired qualita-
tive variables respectively. The Spearman’s correlation
rank test was used to evaluate the significance of cor-
relation. Univariate logistic regression was performed
separately for: adrenaline, noradrenaline and cortisol
as well as age, gender, body mass index, time to pri-
mary percutaneous coronary intervention, HbA1c,
creatine kinase, creatine kinase MB isoenzyme, tropo-
nin I, creatinine, total cholesterol, low-density-
lipoprotein cholesterol, high-density-lipoprotein
cholesterol, triglycerides, hypertension, smoking, fam-
ily history of coronary artery disease and MI localisa-
tion. Multivariate logistic-regression models were
employed to identify independent predictors of stress
hyperglycaemia. Variables in the final model were
selected with a step-down procedure; the decision to
remove terms was based on a likelihood-ratio test
and p-value. Odds ratios (OR) and their 95% confi-
dence intervals (CI) were calculated. Receiver operat-
ing characteristic (ROC) curves were constructed,
and the area under the ROC curve (AUC) was deter-
mined. Statistical significance was indicated by a
p-value < 0.05.
Based on the previous data from large registries
we assumed the occurrence of diabetes in patients
with MI to be 20% (21,22). Similarly, we expected
that 20% of our study participants would develop
stress hyperglycaemia (23). With these assumptions
it was calculated that enrolment of 240 patients
would be mandatory to demonstrate a fourfold
higher prevalence of stress hyperglycaemia in patients
with diabetes than in subjects without diabetes,
allowing for a 99.9% power with a 2-sided a-value
of 0.05.
The statistical analysis and sample size calculation
were carried out using the computer package STAT-
ISTICA 10.0 (Statsoft, Tulsa, USA). In addition,
MedCalc 12.0 (MedCalc Software, Mariakerke, Bel-




Of the total number of 365 patients 24 refused fur-
ther participation in the study: 18 before discharge
from hospital and further six during the first
3 months after the index episode of MI. Seven
patients were excluded from the study during hospi-
talisation because of a false diagnosis of MI (three
patients), dopamine therapy, acute pharyngitis,
chronic obstructive pulmonary disease and suspicion
of a lung tumour (one patient each). Forty-two
patients were excluded from further analysis because
of incomplete data, whereas further 49 did not
attend the 3-month follow-up appointment including
one person who died. The final study group con-
sisted of 243 patients: 58 women (23.9%) and 185
men (76.1%), aged 57.0 ± 9.3 years.
The adverse events observed during 3 months of
follow-up included re-MI (five patients), unstable
angina (17 patients) and development of symptom-
atic chronic heart failure (six patients). In addition,
within 3 months after study enrolment 14 patients
underwent percutaneous coronary intervention
including five subjects with re-MI or unstable angina
and nine patients scheduled for an elective procedure
during the index hospitalisation. Furthermore, at 3-
month follow-up three patients were treated with
elective coronary artery bypass grafting scheduled
during the index hospitalisation.
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Diabetes status
Among the study participants there were 39 (16.0%)
patients with pre-existing diabetes and 204 (84.0%)
with no prior diagnosis of carbohydrate metabolism
abnormalities. In the latter, AGT was diagnosed for
the first time in the acute phase of MI in 92 (45.1%)
cases. Three months after the index MI, carbohydrate
abnormalities regression was observed in 46 (50%)
patients (p < 0.0001), including resolution of
impaired glucose tolerance occurred in 40 (63.5%)
and diabetes in 6 (20.7%) patients originally present-
ing with AGT at day 3. Both changes were statisti-
cally highly significant with p-values below 0.0001.
Of 23 patients diagnosed with diabetes on day 3, the
diagnosis was maintained at month 3 in 12 (52.2%)
cases, whereas reversion into impaired glucose toler-
ance occurred in 11 (47.8%) patients (Table 1).
Twelve subjects who had diabetes mellitus diagnosed
on the basis of both OGTT results from day 3 and
month 3 (4.9% of all patients) were subsequently
incorporated into the pre-existing diabetes group for
further analysis. Altogether the patients with diabetes
constituted 21.0% of the study population. The base-
line characteristics of the studied groups are pre-
sented in Table 2.
There were 34 patients with newly detected
impaired glucose tolerance (14.0% of all patients).
Transient AGT at day 3 was present in 46 and
3 months after discharge in 18 individuals, corre-
sponding to 18.9% and 7.4% of all patients respec-
tively. Patients with impaired glucose tolerance or
diabetes were significantly older comparing with the
normal glucose tolerance group. They were also more
likely to receive inhibitors of renin-angiotensin-aldo-
sterone system, beta-blockers and lipid-lowering
drugs. Furthermore, when compared with the normal
glucose tolerance group, patients with diabetes, but
not with impaired glucose tolerance, showed signifi-
Table 2 Baseline characteristics and prevalence of stress hyperglycaemia in the groups of patients by presence of AGT
Assessed parameter
(mean ± SD) DM n = 51 IGT n = 34
AGT at
D3 n = 46
AGT at M3
n = 18 NGT n = 94
p-value DM
vs. NGT
Age (years) 59.9 ± 8.8 60.8 ± 8.9 56.3 ± 9.7 56.6 ± 6.8 54.5 ± 9.2 0.0052
BMI (kg ⁄ m2) 29.0 ± 3.6 26.4 ± 4.0 27.4 ± 4.6 27.3 ± 5.5 26.0 ± 3.6 0.000067
Time to PTCA (min) 258.0 ± 166.5 248.2 ± 152.3 251.6 ± 173.9 222.2 ± 77.3 259.7 ± 162.0 NS
MI risk factors n (%)
Men 35 (68.6%) 26 (76.5%) 34 (73.9%) 13 (72.2%) 77 (81.9%) NS
Hypertension 32 (62.8%) 14 (41.2%) 18 (39.1%) 10 (55.6%) 29 (30.9%) 0.002
Hyperlipidaemia 15 (29.4%) 9 (26.5%) 10 (21.7%) 4 (22.2%) 21 (22.3%) NS




7 (13.7%) 8 (23.5%) 11 (23.9%) 4 (22.2%) 20 (21.3%) NS
Medication before admission n (%)
ACE or ARB 13 (25.5%) 7 (20.6%) 9 (19.6%) 3 (16.7%) 7 (7.4%) 0.0025
Aspirin 7 (13.7%) 3 (8.8%) 3 (6.5%) 1 (5.6%) 6 (6.4%) NS
Beta-blocker 7 (13.7%) 8 (23.5%) 2 (4.3%) 1 (5.6%) 3 (3.2%) 0.017
Calcium channel
antagonist
8 (15.7%) 3 (8.8%) 4 (8.7%) 2 (11.1%) 5 (5.3%) NS
Diuretic 5 (9.8%) 2 (5.9%) 2 (4.3%) 3 (16.7%) 1 (1.1%) 0.012
Lipid-lowering drugs 9 (17.6%) 7 (20.6%) 1 (2.2%) - 8 (8.5%) NS
Anterior MI localisation
n (%)
29 (56.9%) 13 (38.2%) 24 (52.2%) 8 (44.4%) 36 (38.3%) 0.032
Stress hyperglycaemia
n (%)
28 (54.9%) 3 (8.8%) 1 (2.2%) - 2 (2.1%) < 0.000001
ACE, angiotensin-converting enzyme inhibitor; AGT at D3, abnormal glucose tolerance diagnosed at day 3; AGT at M3, abnormal glu-
cose tolerance diagnosed at month 3; ARB, angiotensin receptor blocker; BMI, body mass index; DM, diabetes mellitus; IGT, impaired
glucosae tolerance; MI, myocardial infarction; NGT, normal glucose tolerance; NS, not significant; PTCA, percutaneous transluminal cor-
onary angioplasty; SD, standard deviation. Significant p-values were also present between: DM vs. IGT for BMI (p = 0.02) and preva-
lence of stress hyperglycaemia (p = 0.000001). DM vs. AGT at D3 for history of hypertension (p = 0.019), therapy with lipid-lowering
drugs (p = 0.013) and prevalence of stress hyperglycaemia (p < 0.000001). IGT vs. AGT at D3 for therapy with beta-blocker
(p = 0.01). IGT vs. AGT at M3 for therapy with beta-blocker (p = 0.022). IGT vs. NGT for age (p = 0.0045), therapy with ACE or ARB
(p = 0.034) and therapy with beta-blocker (p = 0.0003).
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cantly higher incidence of arterial hypertension, more
frequent anterior location of MI as well as greater
values of body mass index. Admission glycaemia and
HbA1c levels in these patients were also significantly
higher than in all remaining groups. No differences
in other parameters between the study groups were
observed (Table 3).
In attempt to identify predictors of previously
undiagnosed diabetes we found that among all vari-
ables from Tables 2 and 3, high admission glycaemia
(OR for a 1 mmol ⁄ l increase 1.35, 95% CI 1.09–1.67;
p < 0.007), elevated HbA1c level (OR for a 1%
increase 2.97, 95% CI 1.57–5.59; p < 0.001), high
fasting blood glucose concentration in OGTT at day
3 (OR for a 1 mmol ⁄ l increase 2.34, 95% CI 1.22–
4.51; p < 0.02), high blood glucose concentration
after 2 h in OGTT at day 3 (OR for a 1 mmol ⁄ l
increase 1.63, 95% CI 1.33–2.00; p < 0.000006) and
increased body mass index (OR for a 1 kg ⁄ m2
increase 1.13, 95% CI 1.01–1.26; p < 0.03) were asso-
ciated with the presence of diabetes in OGTT at
3 months in the univariate analysis. Surprisingly,
multivariate analysis demonstrated high blood glu-
cose concentration after 2 h in OGTT at day 3 (OR
for a 1 mmol ⁄ l increase 1.61, 95% CI 1.26–2.06;
p < 0.00004) as the only predictor of previously
undiagnosed diabetes.
The ROC curve analysis assessing the diagnostic
accuracy for the detection of previously undiagnosed
diabetes revealed the optimal cut-off values of
12.0 mmol ⁄ l for blood glucose concentration after
2 h in OGTT at day 3 (sensitivity 75.0%, specificity
93.6%, positive predictive value 49.9%, negative pre-
dictive value 97.8%), with AUC of 0.88 (95% CI
0.83–0.92).
Rates of major adverse cardiac events including
MI, unstable angina and urgent revascularisation in
patients who completed 3-month follow-up were
comparable between groups with and without diabe-
tes (13.7 vs. 7.8%; p = 0.19). Similarly, the occur-
rence of postinfarct heart failure did not significantly
differ between both groups (2.0 vs. 2.6%; p = 0.81).
Stress hyperglycaemia
Stress hyperglycaemia was present in 34 (14.0%)
patients. A significantly higher incidence of stress
hyperglycaemia was found in patients with diabetes
when compared with all individuals without diabetes
[28 ⁄ 51 (54.9%) vs. 6 ⁄ 192 (3.1%); p < 0.00001]. The
prevalence of stress hyperglycaemia in the other stud-
ied groups was lower than in patients with diabetes,
but no significant between-group differences were
observed (Table 2). Also, in patients with newly diag-
nosed impaired glucose tolerance [3 ⁄ 34 (8.8%);
p < 0.00001] and in patients with AGT at day 3
[1 ⁄ 46 (2.2%); p < 0.000001] the occurrence rate of
stress hyperglycaemia was significantly lower than in
patients with diabetes.
As shown in Figure 1, in patients with stress
hyperglycaemia the adrenaline and cortisol concen-
Table 3 Admission assessed parameters in the groups of patients by presence of AGT (mean ± standard deviation)
Assessed parameter
(unit) DM n = 51 IGT n = 34
AGT at
D3 n = 46
AGT at M3





12.3 ± 4.5 7.7 ± 1.7 7.4 ± 1.5 7.7 ± 1.6 7.4 ± 1.7 < 0.0000001
HbA1c (%) 8.0 ± 1.5 6.2 ± 0.7 6.2 ± 0.9 5.8 ± 0.5 5.9 ± 0.5 < 0.0000001
Adrenaline (lg ⁄ l) 0.14 ± 0.17 0.09 ± 0.12 0.08 ± 0.14 0.09 ± 0.16 0.08 ± 0.16 NS
Noradrenaline (lg ⁄ l) 0.15 ± 0.16 0.12 ± 0.19 0.15 ± 0.23 0.22 ± 0.32 0.16 ± 0.19 NS
Cortisol (lg ⁄ dl) 32.6 ± 18.3 28.2 ± 15.6 29.9 ± 16.1 29.8 ± 17.8 26.1 ± 17.0 NS
CPK (U ⁄ l) 288.3 ± 342.1 382.2 ± 473.4 285.7 ± 327.7 306.5 ± 315.7 349.0 ± 492.4 NS
CK-MB (U ⁄ l) 41.4 ± 61.1 45.1 ± 44.2 46.1 ± 51.7 38.7 ± 32.4 53.0 ± 73.0 NS
Troponin I (ng ⁄ ml) 1.4 ± 2.9 2.4 ± 7.0 1.9 ± 4.3 2.2 ± 4.9 2.5 ± 6.2 NS
Creatinine (lmol ⁄ l) 85.5 ± 17.4 84.7 ± 18.2 86.1 ± 17.4 79.7 ± 14.5 84.8 ± 14.1 NS
Total cholesterol (mmol ⁄ l) 5.5 ± 1.1 6.0 ± 1.4 6.0 ± 1.0 5.9 ± 1.0 5.8 ± 1.2 NS
LDL cholesterol (mmol ⁄ l) 3.5 ± 1.0 3.8 ± 1.1 4.0 ± 0.9 4.0 ± 0.9 3.9 ± 1.1 NS
HDL cholesterol (mmol ⁄ l) 1.3 ± 0.5 1.4 ± 0.4 1.3 ± 0.3 1.3 ± 0.3 1.4 ± 0.3 NS
Triglycerides (mmol ⁄ l) 1.5 ± 1.1 1.7 ± 1.4 1.5 ± 1.1 1.4 ± 1.5 1.1 ± 0.7 NS
AGT at D3, abnormal glucose tolerance diagnosed at day 3; AGT at M3, abnormal glucose tolerance diagnosed at month 3; CPK,
creatine kinase; CK-MB, creatine kinase MB isoenzyme; DM, diabetes mellitus; HbA1c, glycated haemoglobin; HDL, high-density lipopro-
tein; IGT, impaired glucosae tolerance; LDL, low-density lipoprotein; NGT, normal glucose tolerance; NS, not significant. Significant
p-values were also present: for AG between DM vs. IGT (p = 0.000001); DM vs. AGT at D3 (p < 0.0000001) and DM vs. AGT at M3
(p = 0.00038) for HbA1c between DM vs. IGT and AGT groups (p < 0.0000001).
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trations on admission were significantly higher com-
paring with patients without stress hyperglycaemia.
Drugs taken prior to the hospital admission did not
influence stress hormone levels (data not presented).
Univariate analysis demonstrated significant asso-
ciations between stress hyperglycaemia and high
adrenaline and cortisol admission concentrations,
increased body mass index, elevated HbA1c level and
anterior location of MI (Table 4). However, when
tested in the multivariable logistic-regression model
only high admission cortisol concentration, elevated
HbA1c level and anterior wall MI, but not catechol-
amines and body mass index, remained independent
predictors of stress hyperglycaemia (Table 5). Levels
of stress hormones and HbA1c concentration were
unrelated (data not presented).
The ROC curve analysis assessing the diagnostic
accuracy for the detection of stress hyperglycaemia
Figure 1 Comparison of cortisol, adrenaline and noradrenaline concentrations in patients with and without stress
hyperglycaemia





Adrenaline [for a 1 lg ⁄ l increase] 7.20 1.06–48.89 0.042
Noradrenaline [for a 1 lg ⁄ l increase] 1.37 0.25–7.47 0.71
Cortisol [for a 1 lg ⁄ dl increase] 1.04 1.02–1.06 0.00051
Age [for a 1 year increase] 1.03 0.99–1.07 0.12
Body mass index [for a 1 kg ⁄ m2 increase] 1.11 1.02–1.20 0.017
HbA1c [for a 1% increase] 3.79 2.51–5.73 0.0000000002
CK-MB [for a 1 U ⁄ l increase] 0.99 0.99–1.00 0.48
Troponin I [for a 1 ng ⁄ ml increase] 1.00 0.94–1.08 0.92
Creatinine [for a 1 lmol ⁄ l increase] 0.99 0.97–1.02 0.56
Total cholesterol [for a 1 mmol ⁄ l increase] 0.82 0.59–1.15 0.24
LDL cholesterol [for a 1 mmol ⁄ l increase] 0.69 0.46–1.02 0.06
HDL cholesterol [for a 1 mmol ⁄ l increase] 1.09 0.37–3.21 0.87
Triglycerides [for a 1 mmol ⁄ l increase] 1.16 0.88–1.54 0.28
MI risk factors
Men 1.93 0.89–4.22 0.096
Hypertension 1.25 0.60–2.59 0.55
Smoking 1.15 0.64–2.05 0.65
Positive family history of coronary artery disease 1.48 0.64–3.41 0.36
Anterior vs. non-anterior location of MI 2.18 1.03–4.06 0.040
CK-MB, creatine kinase MB isoenzyme; HbA1c, glycated haemoglobin; HDL cholesterol, high-density-lipoprotein cholesterol, triglycerides;
LDL cholesterol , low-density-lipoprotein cholesterol; MI, myocardial infarction.
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revealed the optimal cut-off values of 8.2% for
HbA1c concentration (sensitivity 50.0%, specificity
98.5%, positive predictive value 84.2%, negative pre-
dictive value 92.6%) and 47.7 lg ⁄ dl for admission
cortisol concentration (sensitivity 41.2%, specificity
91.4%, positive predictive value 43.8%, negative pre-
dictive value 90.5%). AUCs for HbA1c concentration
and admission cortisol concentration were 0.86 (95%
CI 0.77–0.94) and 0.67 (95% CI 0.57–0.77) respec-
tively. Comparison of the ROC curves for both
parameters in terms of their diagnostic accuracy
demonstrated the superiority of HbA1c concentration
over admission cortisol concentration (p < 0.02).
Major adverse cardiac events including MI, unsta-
ble angina and urgent revascularisation occurred in 5
(14.7%) and 17 (8.1%) patients who presented on
admission, respectively, with and without stress hy-
perglycaemia (p = 0.21). Similarly, symptoms of
postinfarct heart failure were present in comparable
proportions of subjects from both groups (2.9 vs.
2.4; p = 0.68).
Discussion
The main findings of our study conducted on a
homogenous population of patients with a first MI
with ST-segment elevation are: transient nature of
newly detected AGT in 50% of cases, a huge discrep-
ancy in the prevalence of stress hyperglycaemia
between patients with and without diabetes, and
identification of elevated HbA1c, anterior MI and
high admission cortisol concentration as independent
predictors of stress hyperglycaemia.
Carbohydrate metabolism abnormalities are almost
twice as common in patients with acute MI than in
individuals without ischemic heart disease (24,25).
The Euro Heart Survey reported a 36% incidence of
new onset impaired glucose tolerance and 22% of
newly diagnosed diabetes in acute MI patients,
whereas 31% of the study population had confirmed
diabetes prior to acute MI (16). In our study, the
prevalence of carbohydrate metabolism abnormalities
was lower, regardless of whether diabetes preceded
acute MI (16% of patients) or AGT was diagnosed
for the first time during the index hospitalisation
(45% compared with 58% in the Euro Heart Sur-
vey). A study by Wallander et al. indicates a progres-
sive age-related deterioration in the function of the
pancreatic beta-cells as a major cause of carbohydrate
metabolism abnormalities in elderly people and the
mechanism underlying AGT during acute MI (26).
The progressive deterioration of the beta-cell func-
tion that occurs as an individual ages can result in
an inability to respond appropriately to a stress-
induced (i.e. during acute MI) increase in insulin
resistance. In our opinion the reduction in the size
of the studied groups with carbohydrate metabolism
abnormalities observed in our study with respect to
the Euro Heart Survey (16), is likely because of
younger age of our patients (mean age 57 vs.
66 years in the Euro Heart Survey) and a more
homogeneous cohort, as only patients with a first
episode of MI were recruited into our study. The
lower age of our cohort would suggest that the pan-
creatic beta-cell impairment was probably less fre-
quent in our study population. This assumption
might also explain why in a half of those patients
who presented with AGT at day 3, the presence of
carbohydrate metabolism abnormalities was not con-
firmed by a subsequent OGTT 3 months post-MI
(Table 1). Our results are concordant with findings
by Knudsen et al. obtained in a relatively young
(median age of 58 years) cohort of 224 patients with
predominantly first MI (92.9% of subjects) (27).
However, they substantially differ from those deliv-
ered by the analysis of an older population of
patients (mean age 63.5 years) unselected with
respect to the number of previous MIs too (28). The
latter found the incidence of AGT at 4 days and at
3 months post-MI to be similar, suggesting that in
this population AGT diagnosed for the first time
after MI was not because of stress hyperglycaemia,
but rather because of pre-existing abnormalities. In
our opinion, evaluation of the prevalence of AGT in
patients with a first MI requires further research on
a larger population.
Stress hyperglycaemia in our study was present in
55% of patients with diabetes compared with just 3%
of those without diabetes, despite the high incidence
of AGT (45%) as indicated by OGTT measurements
at day 3 (Table 1). The prevalence of stress hyper-
glycaemia in the setting of acute MI in our cohort
was similar to that previously reported for patients
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HbA1c, glycated haemoglobin; MI, myocardial infarction.
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with diabetes, but significantly lower (3 vs. 13–20%)
than that described by other researchers for individu-
als without diabetes (29,30). However, it should be
emphasised that diabetes might have been underdiag-
nosed in many studies evaluating stress hyperglyca-
emia including majority of these reporting on poor
prognosis in patients with admission hyperglycaemia
without underlying diabetes (3–6,13, 14,29–32). In
these, mostly retrospective design studies, diabetes
mellitus was considered present if, before the study
enrolment, a patient had been informed of this diag-
nosis and was on prescribed treatment for diabetes.
Therefore, the unfavourable prognosis demonstrated
in these data in patients with seemingly pure stress
hyperglycaemia (i.e. without underlying diabetes)
may in fact be at least partially driven by subjects
with unrecognised diabetes. Another possible expla-
nation for the difference in the prevalence of stress
hyperglycaemia in patients without diabetes is, again,
younger age (57 vs. 70 years) and a better beta cells
function of our study population compared with
those in the quoted reports (29,30).
Wong et al. on the basis of the analysis of a sub-
population of patients from ‘The Hyperglycemia:
Intensive Insulin Infusion In Infarction (HI-5)
Study’ postulate the pre-existence of AGT and a
stronger stress reaction in patients with a more seri-
ous disease course to be the basic mechanisms of
stress hyperglycaemia occurrence in patients with MI
(33). They base their conclusions on significantly
higher cortisol values on admission in the group
without AGT. In our research although, the absence
of AGT had no influence on the levels of stress hor-
mones (Table 3). However, stress hyperglycaemia
was related with significantly higher blood plasma
adrenaline and cortisol, but noradrenaline, levels on
admission (Table 4). The acute response to stress
includes immediate (up to 15 min) secretion of both
catecholamines (34). Our results are compatible with
the observations by McGuinness et al. who demon-
strated in an animal model a pronounced stimula-
tory impact of adrenaline on glucose production,
principally by enhancing hepatic glycogenolysis,
whereas noradrenaline exerts only a minimal effect
(35). The lack of admission adrenaline concentration
among independent risk factors of stress hyperglyca-
emia is probably because of the delay between the
onset of stress (often > 4 h from the onset of myo-
cardial pain) and subsequent measurement (Table 5).
Cortisol may be a better marker of MI-related meta-
bolic stress, because of a later secretion onset and
prolonged systemic persistence. Unfortunately, the
study by Wong et al. did not take account of the
time from pain onset to admission (33). Therefore,
it is possible that the delay in the group without
AGT was significantly shorter and for that reason
higher cortisol concentrations were observed there.
The MI clinical symptoms in patients with AGT are
considerably less intensified, and a weaker pain reac-
tion is often a cause of delayed admission to the car-
diology department. The stress accompanying an
acute disease seems to influence the increase of
glycaemia similarly in patients with and without dia-
betes, however, in the former, because of initially
higher plasma glucose concentrations, it will subse-
quently result in significantly higher glycaemia levels.
The comparison of stress hyperglycaemia prevalence
with other forms of AGT requires further research
with special concern of the time passing from pain
onset to hospital admission.
The independent predictors of stress hyperglyca-
emia (besides previously discussed admission corti-
sol) comprised elevated HbA1c and anterior MI.
HbA1c, as the best-known diabetes control parame-
ter, has been recommended by The American Diabe-
tes Association since 2011 to diagnose diabetes, with
a threshold of ‡ 6.5% (20). The fact that high HbA1c
levels make the occurrence of admission glycaemia
‡ 11.1 mmol ⁄ l significantly more likely, clearly indi-
cates a substantially higher probability of stress
hyperglycaemia occurrence in the group with a first
MI with ST-segment elevation and diabetes, in contrast
to patients with a negative history of carbohydrate
metabolism abnormalities. On the other hand, ele-
vated HbA1c concentration, in contrast to high
blood glucose level after 2 h in OGTT at day 3, failed
to be an independent marker of previously undiag-
nosed diabetes in our study.
Anterior MI in comparison with other localisa-
tions usually results in a larger area of myocardial
necrosis and a stronger stimulation of adrenergic and
hormonal system in response to stress, possibly con-
stituting one of the mechanisms influencing glyca-
emia in MI patients (36–38).
Our study has several limitations. First, it lacks
adequate power to assess clinical end points. The low
rate of clinical events observed in our patients is dri-
ven by the high efficacy of modern MI management,
medium-term follow-up and application of strict
inclusion and exclusion criteria. However, these cri-
teria were established to eliminate many of potential
confounders. Second, the reproducibility of OGTT in
the diagnosis of AGT in patients after percutaneous
coronary intervention has been reported to be poor
(39). In this context, the source of doubt is the
group consisting of patients with carbohydrates
metabolism abnormalities recognised no sooner than
in OGTT conducted 3 months after discharge
(Table 1). Third, no account of time from the onset
of infarction pain to revascularisation that might
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have influenced the results of biochemical measure-
ments (especially concentrations of catecholamines)
has been taken. However, the time delay is not a
parameter frequently mentioned in other studies and
its assessment is often unreliable, particularly in
patients with diabetes who present with less typical
MI symptoms.
Conclusions
Newly detected AGT in patients with a first MI with
ST-segment elevation is transient in 50% of cases.
Stress hyperglycaemia is a common finding in
patients with first MI and concomitant diabetes
mellitus, but is rarely seen in patients with impaired
glucose tolerance or transient AGT diagnosed for the
first time during the acute phase of MI. The risk
factors of its occurrence include elevated HbA1c,
anterior MI and high admission cortisol concentration.
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wicz and B. Beszczyńska. Statistical analysis: P. Mag-
ielski. Analysis and interpretation of data: A. Bronisz,
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kliniczne dotyczące postępowania u chorych na cu-
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